Menu

Press Releases

Date Summary View
Toggle Summary RedHill to initiate PIIa Multiple Sclerosis study with RHB-104 following positive pre-clinical studies View HTML
Toggle Summary (Hebrew) RedHill Biopharma filed a registration statement for NASDAQ listing View HTML
Toggle Summary RedHill Biopharma filed a registration statement for NASDAQ listing View HTML
Toggle Summary (Hebrew) RedHill Biopharma announces successful pivotal bioequivalence trial results with RHB-103 (migraine) View HTML
Toggle Summary RedHill announces successful pivotal BE trial results with RHB-103 (Migraine) View HTML
Toggle Summary (Hebrew) RedHill Biopharma commenced advanced clinical trial with RHB-103 (migraine) View HTML
Toggle Summary RedHill Biopharma commenced advanced clinical trial with RHB-103 (migraine) View HTML
Toggle Summary (Hebrew) RedHill Biopharma announces successful pivotal bioequivalence trial results with RHB-102 (prevention of nausea and vomiting) View HTML
Toggle Summary RedHill Biopharma announces successful pivotal bioequivalence trial results with RHB-102 (prevention of nausea and vomiting) View HTML
Toggle Summary (Hebrew) See Dror Ben Asher (CEO) and Gilead Raday's (VP Product Development) TV interview regarding RHB-102 trial results
(Hebrew) See Dror Ben Asher (CEO) and Gilead Raday's (VP Product Development) TV interview regarding RHB-102 trial results ...
View HTML